+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

FASN Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Application

  • PDF Icon

    Report

  • 118 Pages
  • February 2024
  • Region: Global
  • Prof Research
  • ID: 5728497

Quick Summary:

In an increasingly globalized world, understanding the pulse of markets across disparate regions holds critical significance. In the complex landscape of the FASN Inhibitor market, the key to securing competitive advantage lies in accessing reliable, detailed, and up-to-date market information. Our comprehensive market research report fills this gap by delivering valuable insights that can drive strategic business decisions.

The report extensively covers the FASN Inhibitor global market, diving deep into regional dynamics across North America, South America, the Asia Pacific, Europe, and MEA to ensure a broad spectrum analysis. It delves meticulously into company profiles, revealing aspects like business information, SWOT analysis, and market share. Furthermore, it explores the application segments of FASN Inhibitors, addressing significant avenues like liver diseases and cancer treatments. By breaking down complex market structures and dynamics, this report equips businesses with the penetrative market knowledge they need to thrive.

This report describes the global market size of FASN Inhibitor from 2019 to 2023 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2029 and its CAGR from 2024 to 2029.

For the geography segment; regional supply, demand, major players, and price is presented from 2019 to 2029.

This report covers the following regions:

  • North America
  • South America
  • Asia & Pacific
  • Europe
  • MEA
The key countries for each region are also included, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

For the competitor segment, the report includes global key players as well as some small players.

The information for each competitor includes:

  • Company Profile
  • Business Information
  • SWOT Analysis
  • Revenue, Gross Margin and Market Share

Applications Segment:

  • Liver diseases
  • Cancer

Companies Covered:

  • Akero Therapeutics Inc.
  • Bristol-Myers Squibb
  • CymaBay Therapeutics Inc.
  • Enanta Pharmaceuticals Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences
  • Intercept Pharmaceuticals Inc.
  • Inventiva S.A.
  • Madrigal Pharmaceuticals Inc.
  • Metacrine
  • NGM Biopharmaceuticals Inc.
  • Novartis
  • Pfizer
Base Year: 2024
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2029


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
5.6 COVID-19 Impact
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Fasn Inhibitor Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Fasn Inhibitor Market in North America (2019-2029)
8.1 Fasn Inhibitor Market Size
8.2 Fasn Inhibitor Market by End Use
8.3 Competition by Players/Suppliers
8.4 Fasn Inhibitor Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Fasn Inhibitor Market in South America (2019-2029)
9.1 Fasn Inhibitor Market Size
9.2 Fasn Inhibitor Market by End Use
9.3 Competition by Players/Suppliers
9.4 Fasn Inhibitor Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Fasn Inhibitor Market in Asia & Pacific (2019-2029)
10.1 Fasn Inhibitor Market Size
10.2 Fasn Inhibitor Market by End Use
10.3 Competition by Players/Suppliers
10.4 Fasn Inhibitor Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Fasn Inhibitor Market in Europe (2019-2029)
11.1 Fasn Inhibitor Market Size
11.2 Fasn Inhibitor Market by End Use
11.3 Competition by Players/Suppliers
11.4 Fasn Inhibitor Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Fasn Inhibitor Market in MEA (2019-2029)
12.1 Fasn Inhibitor Market Size
12.2 Fasn Inhibitor Market by End Use
12.3 Competition by Players/Suppliers
12.4 Fasn Inhibitor Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Fasn Inhibitor Market (2019-2024)
13.1 Fasn Inhibitor Market Size
13.2 Fasn Inhibitor Market by End Use
13.3 Competition by Players/Suppliers
13.4 Fasn Inhibitor Market Size by Type
Chapter 14 Global Fasn Inhibitor Market Forecast (2024-2029)
14.1 Fasn Inhibitor Market Size Forecast
14.2 Fasn Inhibitor Application Forecast
14.3 Competition by Players/Suppliers
14.4 Fasn Inhibitor Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Akero Therapeutics Inc.
15.1.1 Company Profile
15.1.2 Main Business and FASN Inhibitor Information
15.1.3 SWOT Analysis of Akero Therapeutics Inc.
215.1.4 Akero Therapeutics Inc. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.2 Bristol-Myers Squibb
15.2.1 Company Profile
15.2.2 Main Business and FASN Inhibitor Information
15.2.3 SWOT Analysis of Bristol-Myers Squibb
215.2.4 Bristol-Myers Squibb FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.3 CymaBay Therapeutics Inc.
15.3.1 Company Profile
15.3.2 Main Business and FASN Inhibitor Information
15.3.3 SWOT Analysis of CymaBay Therapeutics Inc.
215.3.4 CymaBay Therapeutics Inc. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.4 Enanta Pharmaceuticals Inc.
15.4.1 Company Profile
15.4.2 Main Business and FASN Inhibitor Information
15.4.3 SWOT Analysis of Enanta Pharmaceuticals Inc.
215.4.4 Enanta Pharmaceuticals Inc. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.5 Galmed Pharmaceuticals Ltd.
15.5.1 Company Profile
15.5.2 Main Business and FASN Inhibitor Information
15.5.3 SWOT Analysis of Galmed Pharmaceuticals Ltd.
215.5.4 Galmed Pharmaceuticals Ltd. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.6 Gilead Sciences
15.6.1 Company Profile
15.6.2 Main Business and FASN Inhibitor Information
15.6.3 SWOT Analysis of Gilead Sciences
215.6.4 Gilead Sciences FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.7 Intercept Pharmaceuticals Inc.
15.7.1 Company Profile
15.7.2 Main Business and FASN Inhibitor Information
15.7.3 SWOT Analysis of Intercept Pharmaceuticals Inc.
215.7.4 Intercept Pharmaceuticals Inc. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.8 Inventiva S.A.
15.8.1 Company Profile
15.8.2 Main Business and FASN Inhibitor Information
15.8.3 SWOT Analysis of Inventiva S.A.
215.8.4 Inventiva S.A. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.9 Madrigal Pharmaceuticals Inc.
15.9.1 Company Profile
15.9.2 Main Business and FASN Inhibitor Information
15.9.3 SWOT Analysis of Madrigal Pharmaceuticals Inc.
215.9.4 Madrigal Pharmaceuticals Inc. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.10 Metacrine
15.10.1 Company Profile
15.10.2 Main Business and FASN Inhibitor Information
15.10.3 SWOT Analysis of Metacrine
215.10.4 Metacrine FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.11 NGM Biopharmaceuticals Inc.
15.11.1 Company Profile
15.11.2 Main Business and FASN Inhibitor Information
15.11.3 SWOT Analysis of NGM Biopharmaceuticals Inc.
215.11.4 NGM Biopharmaceuticals Inc. FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.12 Novartis
15.12.1 Company Profile
15.12.2 Main Business and FASN Inhibitor Information
15.12.3 SWOT Analysis of Novartis
215.12.4 Novartis FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
15.13 Pfizer
15.13.1 Company Profile
15.13.2 Main Business and FASN Inhibitor Information
15.13.3 SWOT Analysis of Pfizer
215.13.4 Pfizer FASN Inhibitor Revenue, Gross Margin and Market Share (2019-2024)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Fasn Inhibitor Report
Table Data Sources of Fasn Inhibitor Report
Table Major Assumptions of Fasn Inhibitor Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Fasn Inhibitor Picture
Table Fasn Inhibitor Classification
Table Fasn Inhibitor Applications
Table Drivers of Fasn Inhibitor Market
Table Restraints of Fasn Inhibitor Market
Table Opportunities of Fasn Inhibitor Market
Table Threats of Fasn Inhibitor Market
Table COVID-19 Impact For Fasn Inhibitor Market
Table Raw Materials Suppliers
Table Different Production Methods of Fasn Inhibitor
Table Cost Structure Analysis of Fasn Inhibitor
Table Key End Users
Table Latest News of Fasn Inhibitor Market
Table Merger and Acquisition
Table Planned/Future Project of Fasn Inhibitor Market
Table Policy of Fasn Inhibitor Market
Table 2019-2029 North America Fasn Inhibitor Market Size
Figure 2019-2029 North America Fasn Inhibitor Market Size and CAGR
Table 2019-2029 North America Fasn Inhibitor Market Size by Application
Table 2019-2024 North America Fasn Inhibitor Key Players Revenue
Table 2019-2024 North America Fasn Inhibitor Key Players Market Share
Table 2019-2029 North America Fasn Inhibitor Market Size by Type
Table 2019-2029 United States Fasn Inhibitor Market Size
Table 2019-2029 Canada Fasn Inhibitor Market Size
Table 2019-2029 Mexico Fasn Inhibitor Market Size
Table 2019-2029 South America Fasn Inhibitor Market Size
Figure 2019-2029 South America Fasn Inhibitor Market Size and CAGR
Table 2019-2029 South America Fasn Inhibitor Market Size by Application
Table 2019-2024 South America Fasn Inhibitor Key Players Revenue
Table 2019-2024 South America Fasn Inhibitor Key Players Market Share
Table 2019-2029 South America Fasn Inhibitor Market Size by Type
Table 2019-2029 Brazil Fasn Inhibitor Market Size
Table 2019-2029 Argentina Fasn Inhibitor Market Size
Table 2019-2029 Chile Fasn Inhibitor Market Size
Table 2019-2029 Peru Fasn Inhibitor Market Size
Table 2019-2029 Asia & Pacific Fasn Inhibitor Market Size
Figure 2019-2029 Asia & Pacific Fasn Inhibitor Market Size and CAGR
Table 2019-2029 Asia & Pacific Fasn Inhibitor Market Size by Application
Table 2019-2024 Asia & Pacific Fasn Inhibitor Key Players Revenue
Table 2019-2024 Asia & Pacific Fasn Inhibitor Key Players Market Share
Table 2019-2029 Asia & Pacific Fasn Inhibitor Market Size by Type
Table 2019-2029 China Fasn Inhibitor Market Size
Table 2019-2029 India Fasn Inhibitor Market Size
Table 2019-2029 Japan Fasn Inhibitor Market Size
Table 2019-2029 South Korea Fasn Inhibitor Market Size
Table 2019-2029 Southeast Asia Fasn Inhibitor Market Size
Table 2019-2029 Australia Fasn Inhibitor Market Size
Table 2019-2029 Europe Fasn Inhibitor Market Size
Figure 2019-2029 Europe Fasn Inhibitor Market Size and CAGR
Table 2019-2029 Europe Fasn Inhibitor Market Size by Application
Table 2019-2024 Europe Fasn Inhibitor Key Players Revenue
Table 2019-2024 Europe Fasn Inhibitor Key Players Market Share
Table 2019-2029 Europe Fasn Inhibitor Market Size by Type
Table 2019-2029 Germany Fasn Inhibitor Market Size
Table 2019-2029 France Fasn Inhibitor Market Size
Table 2019-2029 United Kingdom Fasn Inhibitor Market Size
Table 2019-2029 Italy Fasn Inhibitor Market Size
Table 2019-2029 Spain Fasn Inhibitor Market Size
Table 2019-2029 Belgium Fasn Inhibitor Market Size
Table 2019-2029 Netherlands Fasn Inhibitor Market Size
Table 2019-2029 Austria Fasn Inhibitor Market Size
Table 2019-2029 Poland Fasn Inhibitor Market Size
Table 2019-2029 Russia Fasn Inhibitor Market Size
Table 2019-2029 MEA Fasn Inhibitor Market Size
Figure 2019-2029 MEA Fasn Inhibitor Market Size and CAGR
Table 2019-2029 MEA Fasn Inhibitor Market Size by Application
Table 2019-2024 MEA Fasn Inhibitor Key Players Revenue
Table 2019-2024 MEA Fasn Inhibitor Key Players Market Share
Table 2019-2029 MEA Fasn Inhibitor Market Size by Type
Table 2019-2029 Egypt Fasn Inhibitor Market Size
Table 2019-2029 Israel Fasn Inhibitor Market Size
Table 2019-2029 South Africa Fasn Inhibitor Market Size
Table 2019-2029 Gulf Cooperation Council Countries Fasn Inhibitor Market Size
Table 2019-2029 Turkey Fasn Inhibitor Market Size
Table 2019-2024 Global Fasn Inhibitor Market Size by Region
Table 2019-2024 Global Fasn Inhibitor Market Size Share by Region
Table 2019-2024 Global Fasn Inhibitor Market Size by Application
Table 2019-2024 Global Fasn Inhibitor Market Share by Application
Table 2019-2024 Global Fasn Inhibitor Key Vendors Revenue
Figure 2019-2024 Global Fasn Inhibitor Market Size and Growth Rate
Table 2019-2024 Global Fasn Inhibitor Key Vendors Market Share
Table 2019-2024 Global Fasn Inhibitor Market Size by Type
Table 2019-2024 Global Fasn Inhibitor Market Share by Type
Table 2024-2029 Global Fasn Inhibitor Market Size by Region
Table 2024-2029 Global Fasn Inhibitor Market Size Share by Region
Table 2024-2029 Global Fasn Inhibitor Market Size by Application
Table 2024-2029 Global Fasn Inhibitor Market Share by Application
Table 2024-2029 Global Fasn Inhibitor Key Vendors Revenue
Figure 2024-2029 Global Fasn Inhibitor Market Size and Growth Rate
Table 2024-2029 Global Fasn Inhibitor Key Vendors Market Share
Table 2024-2029 Global Fasn Inhibitor Market Size by Type
Table 2024-2029 Fasn Inhibitor Global Market Share by Type

Companies Mentioned

  • Akero Therapeutics Inc.
  • Bristol-Myers Squibb
  • CymaBay Therapeutics Inc.
  • Enanta Pharmaceuticals Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences
  • Intercept Pharmaceuticals Inc.
  • Inventiva S.A.
  • Madrigal Pharmaceuticals Inc.
  • Metacrine
  • NGM Biopharmaceuticals Inc.
  • Novartis
  • Pfizer
  • Terns Pharmaceuticals Inc.
  • Viking Therapeutics Inc.
  • Sagimet Biosciences Inc.

Methodology

Loading
LOADING...